The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL
Open accessAbstract
Key Points: CC-122 is a novel agent for DLBCL with antitumor and immunomodulatory activity. CC-122 binds CRBN and degrades Aiolos and Ikaros resulting in a mimicry of IFN signaling and apoptosis in DLBCL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Examination of published proteome-wide mass spectrometry data confirmed degradation of endogenous, full-length WIZ in WSU-DLCL2 (human diffuse large B cell lymphoma) and TMD8 (human diffuse large B cell lymphoma) cells in the presence of lenalidomide and the thalidomide analog CC-122 (fig. S7C) (20).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [20]
In the citing paper
“Thalidomide, lenalidomide and pomalidomide are currently FDA approved in a variety of clinical settings, including MM, NHL and MDS as well as Kaposi sarcoma (KS)19–22.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Stromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G. W., Davé, S. S., Xiao, W., Powell, J. I., Zhao, H., Xu, W., Tan, B. T., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,847
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Self-citationFeugier, P., Hoof, A. V., Sebban, C., Solal-Céligny, P., Bouabdallah, R., Fermé, C., Christian, B., Lepage, É., Tilly, H., Morschhauser, F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.131 · Cited by 1,487
Armitage, J. O., & Weisenburger, D. D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2780 · Cited by 1,259
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141
Scott, D. W., Wright, G. W., Williams, P. M., Lih, C., Walsh, W. D., Jaffe, E. S., Rosenwald, A., Campo, E., Chan, W. C., Connors, J. M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-536433 · Cited by 639
Gandhi, A. K., Kang, J., Havens, C. G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M. F., Thakurta, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12708 · Cited by 619
Self-citationBarrans, S., Crouch, S., Smith, A. G., Turner, K., Owen, R. G., Patmore, R. D., Roman, E., & Jack, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3947 · Cited by 552
Cited by
Sorted by citations
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
Sievers, Q. L., Petzold, G., Bunker, R. D., Renneville, A., Słabicki, M., Liddicoat, B. J., Abdulrahman, W., Mikkelsen, T., Ebert, B. L., & Thomä, N. H. (2018) · Science · doi:10.1126/science.aat0572 · Cited by 537
“Consistent with our earlier finding that CC-122 and CC-220 were capable of degrading ZFs not affected by pomalidomide, all three thalidomide analogs exhibited distinct ZF degradation patterns across the ZF library (Fig.”
MethodInfluentialMolecular Glues for Targeted Protein Degradation: From Serendipity to Rational Discovery
Dong, G., Ding, Y., He, S., & Sheng, C. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00895 · Cited by 369
Targeted protein degradation: advances in drug discovery and clinical practice
Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326
Small-Molecule Modulation of Protein Homeostasis
Burslem, G. M., & Crews, C. M. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00077 · Cited by 298
Diffuse large B-cell lymphoma: R-CHOP failure—what to do?
Coiffier, B., & Sarkozy, C. (2016) · Hematology · doi:10.1182/asheducation-2016.1.366 · Cited by 294
Nowakowski, G. S., Chiappella, A., Gascoyne, R. D., Scott, D. W., Zhang, Q., Jurczak, W. J., Özcan, M., Hong, X., Zhu, J., Jin, J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01366 · Cited by 280
Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic
Sasso, J. M., Tenchov, R., Wang, D.-S., Johnson, L. S., Wang, X., & Zhou, Q. A. (2022) · Biochemistry · doi:10.1021/acs.biochem.2c00245 · Cited by 264
Surka, C., Jin, L., Mbong, N., Lu, C.-C., Jang, I. S., Rychak, E., Mendy, D., Clayton, T., Tindall, E., Hsu, C., et al. (2021) · Blood · doi:10.1182/blood.2020008676 · Cited by 229
Self-citationTargeted Protein Degradation by Small Molecules
Bondeson, D. P., & Crews, C. M. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103507 · Cited by 207
Targeted protein degradation as a powerful research tool in basic biology and drug target discovery
Wu, T., Yoon, H., Xiong, Y., Dixon-Clarke, S. E., Nowak, R. P., & Fischer, E. S. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0438-0 · Cited by 186
Phenyl‐Glutarimides: Alternative Cereblon Binders for the Design of PROTACs
Min, J., Mayasundari, A., Keramatnia, F., Jonchère, B., Yang, S. W., Jarusiewicz, J., Actis, M., Das, S., Young, B. M., Slavish, J., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202108848 · Cited by 181
Haven't got a glue: Protein surface variation for the design of molecular glue degraders
Kozicka, Z., & Thomä, N. H. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.009 · Cited by 170
Camicia, R., Winkler, H. C., & Hassa, P. O. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0474-2 · Cited by 177
Czuczman, M. S., Trněný, M., Davies, A. J., Rule, S. A., Linton, K., Wagner‐Johnston, N. D., Gascoyne, R. D., Slack, G. W., Brousset, P., Eberhard, D. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2818 · Cited by 163
Self-citationFrom Discovery to Bedside: Targeting the Ubiquitin System
Wertz, I. E., & Wang, X. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.10.022 · Cited by 162
Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals
Russak, E. M., & Bednarczyk, E. M. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018797110 · Cited by 146
Collins, I., Wang, H., Caldwell, J., & Chopra, R. (2017) · Biochemical Journal · doi:10.1042/bcj20160762 · Cited by 139
Self-citationCancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
p63 is a cereblon substrate involved in thalidomide teratogenicity
Asatsuma-Okumura, T., Ando, H., De Simone, M., Yamamoto, J., Sato, T., Shimizu, N., Asakawa, K., Yamaguchi, Y., Ito, T., Guerrini, L., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0366-7 · Cited by 134
Sievers, Q. L., Gasser, J. A., Cowley, G. S., Fischer, E. S., & Ebert, B. L. (2018) · Blood · doi:10.1182/blood-2018-01-821769 · Cited by 124
Molecular mechanisms of thalidomide and its derivatives
Ito, T., & Handa, H. (2020) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.96.016 · Cited by 123
Poggi, A. D., Varesano, S., & Zocchi, M. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00262 · Cited by 113
Novel immunomodulatory drugs and neo-substrates
Gao, S., Wang, S., & Song, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-0182-y · Cited by 95
A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies
Rasco, D. W., Papadopoulos, K. P., Pourdehnad, M., Gandhi, A. K., Hagner, P. R., Li, Y., Wei, X., Chopra, R., Hege, K. M., DiMartino, J. F., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1203 · Cited by 94
Self-citationARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells
Yamamoto, J., Suwa, T., Murase, Y., Tateno, S., Mizutome, H., Asatsuma‐Okumura, T., Shimizu, N., Kishi, T., Momose, S., Kizaki, M., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0645-3 · Cited by 90
IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos
Fedele, P. L., Willis, S. N., Liao, Y., Low, M. S. Y., Rautela, J., Segal, D., Gong, J., Huntington, N. D., Shi, W., Huang, D. C. S., et al. (2018) · Blood · doi:10.1182/blood-2018-05-850727 · Cited by 94
Advances in immunotherapeutic research for glioma therapy
Miyauchi, J. T., & Tsirka, S. E. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8695-5 · Cited by 90
Molecular Mechanisms of the Teratogenic Effects of Thalidomide
Asatsuma‐Okumura, T., Ito, T., & Handa, H. (2020) · Pharmaceuticals · doi:10.3390/ph13050095 · Cited by 88
Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs
Ito, T., & Handa, H. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2073-4 · Cited by 84
Yang, K., Zhao, Y., Nie, X., Wu, H., Wang, B., Almodóvar‐Rivera, C. M., Xie, H., & Tang, W. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.04.008 · Cited by 80
UBE2G1 governs the destruction of cereblon neomorphic substrates
Lu, G., Weng, S., Matyskiela, M., Zheng, X., Fang, W., Wood, S., Surka, C., Mizukoshi, R., Lu, C.-C., Mendy, D., et al. (2018) · eLife · doi:10.7554/elife.40958 · Cited by 78
Self-citationMolecular mechanisms of cereblon-based drugs
Asatsuma‐Okumura, T., Ito, T., & Handa, H. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.004 · Cited by 80
Advancing Strategies for Proteolysis-Targeting Chimera Design
Li, M., Zhi, Y., Liu, B., & Yao, Q. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01555 · Cited by 78
Carpio, C., Bouabdallah, R., Ysebaert, L., Sancho, J.-M., Salles, G., Cordoba, R., Pinto, A., Gharibo, M., Rasco, D., Panizo, C., et al. (2020) · Blood · doi:10.1182/blood.2019002395 · Cited by 72
Self-citationInducing protein-protein interactions with molecular glues
Che, Y., Gilbert, A. M., Shanmugasundaram, V., & Noe, M. C. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.04.046 · Cited by 72
Monomeric Targeted Protein Degraders
Hanan, E. J., Liang, J., Wang, X., Blake, R. A., Blaquiere, N., & Staben, S. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00093 · Cited by 69
Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation
Yamanaka, S., Furihata, H., Yanagihara, Y., Taya, A., Nagasaka, T., Usui, M., Nagaoka, K., Shoya, Y., Nishino, K., Yoshida, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40385-9 · Cited by 73
Computer-Aided Drug Discovery for Undruggable Targets
Sun, Q., Wang, H., Xie, J., Wang, L., Mu, J., Li, J., Ren, Y., & Lai, L. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00969 · Cited by 72
Sperling, A. S., Burgess, M. W., Keshishian, H., Gasser, J. A., Bhatt, S., Jan, M., Slabicki, M. M., Sellar, R. S., Fink, E. C., Miller, P. G., et al. (2019) · Blood · doi:10.1182/blood.2019000789 · Cited by 65
Ito, T., Yamaguchi, Y., & Handa, H. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.012 · Cited by 60
Unveiling the hidden interactome of CRBN molecular glues
Baek, K., Metivier, R. J., Burman, S. S. R., Bushman, J. W., Yoon, H., Lumpkin, R. J., Ryan, J. K., Abeja, D. M., Lakshminarayan, M., Yue, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62099-w · Cited by 77
Design and Synthesis of Novel Cereblon Binders for Use in Targeted Protein Degradation
Norris, S. H., Ba, X., Rhodes, J., Huang, D., Khambatta, G., Buenviaje, J., Nayak, S. K., Meiring, J., Reiss, S. M., Xu, S., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01848 · Cited by 61
Self-citationGeiger, T. M., Schäfer, S. C., Dreizler, J. K., Walz, M., & Hausch, F. (2021) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2021.100018 · Cited by 57
Akuffo, A. A., Alontaga, A. Y., Metcalf, R. S., Beatty, M. S., Becker, A., McDaniel, J. M., Hesterberg, R. S., Goodheart, W. E., Gunawan, S., Ayaz, M., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.816868 · Cited by 55
Targeting cereblon in hematologic malignancies
Fuchs, O. (2023) · Blood Reviews · doi:10.1016/j.blre.2022.100994 · Cited by 55
Davis, D. A., Mishra, S., Anagho, H. A., Aisabor, A. I., Shrestha, P., Wang, V., Takamatsu, Y., Maeda, K., Mitsuya, H., Zeldis, J. B., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17960 · Cited by 54
The molecular mechanism of thalidomide analogs in hematologic malignancies
Lindner, S., & Krönke, J. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1450-z · Cited by 51
The Challenge of Primary Central Nervous System Lymphoma
Carnevale, J. C., & Rubenstein, J. L. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.07.013 · Cited by 51
The IKZF1–IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages
Mougiakakos, D., Bach, C., Böttcher, M., Beier, F., Röhner, L., Stoll, A., Rehli, M., Gebhard, C., Lischer, C., Eberhardt, M., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0555 · Cited by 51
Ioannou, N., Hagner, P. R., Stokes, M., Gandhi, A. K., Apollonio, B., Fanous, M., Papazoglou, D., Sutton, L., Rosenquist, R., Amini, R., et al. (2020) · Blood · doi:10.1182/blood.2020006073 · Cited by 49
Self-citationInvestigational drugs for the treatment of diffuse large B-cell lymphoma
Patriarca, A., & Gaïdano, G. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1855140 · Cited by 48
Molecular glues to stabilise protein–protein interactions
Soini, L., Leysen, S., Davis, J., & Ottmann, C. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102169 · Cited by 49
Čermáková, K., & Hodges, H. C. (2018) · Molecules · doi:10.3390/molecules23081958 · Cited by 51
Chiu, H., Trisal, P., Bjorklund, C. C., Carrancio, S., Toraño, E. G., Guarinós, C., Papazoglou, D., Hagner, P. R., Beldi‐Ferchiou, A., Tarte, K., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15797 · Cited by 48
Self-citationAvadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies
Renneville, A., Gasser, J. A., Grinshpun, D. E., Beltran, P. M. J., Udeshi, N. D., Matyskiela, M. E., Clayton, T., McConkey, M. E., Viswanathan, K., Tepper, A., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0105 · Cited by 46
Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges
Ye, P., Chi, X., Cha, J., Luo, S., Yang, G., Yan, X., & Yang, W. (2021) · Cells · doi:10.3390/cells10123309 · Cited by 51
Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell‐mediated cytotoxicity
Hagner, P. R., Chiu, H., Ortiz, M., Apollonio, B., Wang, M., Couto, S. S., Waldman, M. F., Flynt, E., Ramsay, A. G., Trotter, M. W. B., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14866 · Cited by 48
Self-citationMechanisms of lenalidomide sensitivity and resistance
Martínez-Høyer, S., & Karsan, A. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.09.196 · Cited by 48
Routes to molecular glue degrader discovery
Liu, Y., Bai, J., Li, D., & Cang, Y. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.12.006 · Cited by 51
Davis, D. A., Shrestha, P., Aisabor, A. I., Stream, A., Galli, V., Pise-Masison, C. A., Tagawa, T., Ziegelbauer, J. M., Franchini, G., & Yarchoan, R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1546544 · Cited by 44
Repurposing DNA repair factors to eradicate tumor cells upon radiotherapy
Bhattacharya, S., & Asaithamby, A. (2017) · Translational Cancer Research · doi:10.21037/tcr.2017.05.22 · Cited by 44
Identification and selectivity profiling of small-molecule degraders via multi-omics approaches
Scholes, N. S., Mayor‐Ruiz, C., & Winter, G. E. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.03.007 · Cited by 44
Kotb, A. R., Bakhotmah, D. A., Abdallah, A. E., Elkady, H., Taghour, M. S., Eissa, I. H., & El‐Zahabi, M. A. (2022) · RSC Advances · doi:10.1039/d2ra06188k · Cited by 40
Immunomodulatory Drugs for the Treatment of B Cell Malignancies
Ioannou, N., Jain, K., & Ramsay, A. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168572 · Cited by 41
Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy
Chen, S., Chen, Z., Lu, L., Zhao, Y., Zhou, R., Xie, Q., Shu, Y., Lin, J., Yu, X., & Wang, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115403 · Cited by 39
Abdallah, A. E., Eissa, I. H., Mehany, A. B. M., Sakr, H. M., Atwa, A., El‐Adl, K., & El‐Zahabi, M. A. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.135164 · Cited by 39
Applications of protein ubiquitylation and deubiquitylation in drug discovery
Chen, Y., Xue, H., & Jin, J. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107264 · Cited by 41
Molecular glue degraders: exciting opportunities for novel drug discovery
Lemaitre, T., Cornu, M., Schwalen, F., Since, M., Kieffer, C., & Voisin-Chiret, A. S. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2306845 · Cited by 36
Krasavin, M., Adamchik, M., Bubyrev, A. I., Heim, C., Maiwald, S. A., Zhukovsky, D., Zhmurov, P. A., Bunev, A. S., & Hartmann, M. D. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114990 · Cited by 36
Phillips, T. J., Michot, J., & Ribrag, V. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.08.022 · Cited by 34
Michot, J., Bouabdallah, R., Vitolo, U., Doorduijn, J. K., Salles, G., Chiappella, A., Zinzani, P. L., Bijou, F. D., Kersten, M. J., Sarmiento, R., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30208-8 · Cited by 32
Self-citationTargeted Protein Degradation: Clinical Advances in the Field of Oncology
Salama, A. K. A. A., Trkulja, M. V., Casanova, E., & Uras, I. Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315440 · Cited by 36
Li, J., Li, C., Zhang, Z., Zhang, Z., Wu, Z., Liao, J., Wang, Z., McReynolds, M. G., Xie, H., Guo, L., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115567 · Cited by 31
Yamshon, S., & Ruan, J. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00536-6 · Cited by 30
Fu, L., Zhang, J., Shen, B., Kong, L., Liu, Y., Tu, W., Wang, W., Cai, X., Wang, X., Cheng, N., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00103 · Cited by 29
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31
Patil, A., Manzano, M., & Gottwein, E. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019031732 · Cited by 29
Ege, N., Bouguenina, H., Tatari, M. N., & Chopra, R. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.02.011 · Cited by 31
Self-citationA FRET-Based Assay for the Identification and Characterization of Cereblon Ligands
Boichenko, I., Deiss, S., Bär, K., Hartmann, M. D., & Alvarez, B. H. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01735 · Cited by 30
The application of ubiquitin ligases in the PROTAC drug design
Chen, Y., & Jin, J. (2020) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmaa053 · Cited by 29
Feng, Y., Hu, X., & Wang, X. (2024) · Biomarker Research · doi:10.1186/s40364-024-00638-1 · Cited by 30
Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy
Apollonio, B., Ioannou, N., Papazoglou, D., & Ramsay, A. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.626818 · Cited by 27
Takwale, A. D., Kim, E. Y., Jang, Y., Lee, D.-H., Kim, S., Choi, Y., Kim, J. H., Lee, D. Y., Kim, Y., Lee, S. M., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105923 · Cited by 25
Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs
Fuchs, O. (2018) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x18666180522073855 · Cited by 26
Mabrouk, R. R., Abdallah, A. E., Mahdy, H. A., El-Kalyoubi, S. A., Kamal, O., Abdelghany, T. M., Zayed, M. F., Alshaeri, H. K., Alasmari, M. M., & El‐Zahabi, M. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512416 · Cited by 24
CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma
Cubillos‐Zapata, C., Córdoba, R., Ortiz, J. A., Arribas-Jiménez, C., Hernández-Jiménez, E., Toledano, V., Villaescusa, T., Moreno, V., & López‐Collazo, E. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1231290 · Cited by 23
Tong, K. I., Yoon, S., Isaev, K., Bakhtiari, M., Lackraj, T., He, M. Y., Joynt, J., Silva, A., Xu, M. C., Privé, G. G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4027 · Cited by 24
Crbn-based molecular Glues: Breakthroughs and perspectives
An, J., & Zhang, X. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117683 · Cited by 22
Novel Targets for the Treatment of Melanoma
Ambrosi, L., Khan, S. A., Carvajal, R. D., & Yang, J. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0849-4 · Cited by 23
Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes
Hesterberg, R. S., Beatty, M. S., Han, Y., Fernandez, M. R., Akuffo, A. A., Goodheart, W. E., Yang, C., Chang, S., Colin, C., Alontaga, A. Y., et al. (2020) · Blood · doi:10.1182/blood.2019003257 · Cited by 22
Geng, C., Chen, J., Song, T., Jung, J. H., Long, M., Song, M., Ji, T., Min, B. S., Lee, J. G., Peng, B., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.05.012 · Cited by 23
SimPLIT: Simplified Sample Preparation for Large-Scale Isobaric Tagging Proteomics
Sialana, F. J., Roumeliotis, T. I., Bouguenina, H., Hak, L. C. W., Wang, H., Caldwell, J., Collins, I., Chopra, R., & Choudhary, J. S. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00092 · Cited by 20
Self-citationFacilitating the development of molecular glues: Opportunities from serendipity and rational design
Jiang, W., Jiang, Y., Luo, Y., Qiao, W., & Yang, T. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115950 · Cited by 22
Stokes, M. E., Wenzl, K., Huang, C. C., Ortiz, M., Hsu, C.-C., Maurer, M. J., Stong, N., Nakayama, Y., Wu, L., Chiu, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50830-y · Cited by 23
Self-citationLin, W., Li, Y., Min, J., Liu, J., Yang, L., Lee, R. E., Jr., & Chen, T. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00507 · Cited by 21
Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen
Mo, Z., Wood, S., Namiranian, S., Mizukoshi, R., Weng, S., Jang, I. S., Fontanillo, C., Baughman, J. M., Silva-Torres, A., Slade, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003431 · Cited by 20
Self-citationKim, S. Y., Lee, J. Y., Jhin, C., Shin, J. M., Kim, M., Ahn, H. R., Yoo, G., Son, Y., Jung, S. H., & Nho, C. W. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b01488 · Cited by 20
Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms
Guo, H., Yang, J., Wang, H., Liu, X., Liu, Y., & Zhou, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1017990 · Cited by 21
Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma
Abramson, H. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032645 · Cited by 20
Guo, L., Lin, P., Xiong, H., Tu, S., & Chen, G. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.01.001 · Cited by 20
Metadata
- Authors
- Hagner, P. R., Man, H.-W., Fontanillo, C., Wang, M., Couto, S., Breider, M., Bjorklund, C., Havens, C. G., Lu, G., Rychak, E., Raymon, H., Narla, R. K., Barnes, L., Khambatta, G., Chiu, H., Kosek, J., Kang, J., Amantangelo, M. D., Waldman, M., Lopez-Girona, A., Cai, T., Pourdehnad, M., Trotter, M., Daniel, T. O., Schafer, P. H., Klippel, A., Thakurta, A., Chopra, R., & Gandhi, A. K.
- Affiliations
- Celgene (United States) (US)
- Celgene Corporation, Sevilla, Spain;
- Celgene Corporation, San Diego, CA; and
- Celgene Corporation, San Francisco, CA
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2015-08-06
- Volume
- 126
- Issue
- 6
- Pages
- 779-789
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC4528065
- OpenAlex
- W1628369270
- Cited by
- 203
- References
- 36
- Citations by year
- 2026: 9 · 2025: 20 · 2024: 20 · 2023: 24 · 2022: 21 · 2021: 30 · 2020: 24 · 2019: 12 · 2018: 18 · 2017: 12 · 2016: 11 · 2015: 2
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research UK (11566)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- cereblon, lenalidomide, pomalidomide, Aiolos, Ikaros, diffuse large B-cell lymphoma, interferon-stimulated genes, interferon response, ubiquitination, protein degradation, apoptosis, germinal center B-cell DLBCL, T cells, immunomodulators
- MeSH terms
- Lenalidomide, Animals, Antineoplastic Agents, B-Lymphocytes, Humans, Interferons, Peptide Hydrolases, Piperidones, T-Lymphocytes, Thalidomide, Signal Transduction, Gene Expression Regulation, Neoplastic, Lentivirus, Lymphoma, Large B-Cell, Diffuse, Mice, SCID, Molecular Mimicry, Xenograft Model Antitumor Assays, RNA, Small Interfering, Ubiquitin-Protein Ligases, Cell Line, Tumor, Adaptor Proteins, Signal Transducing, Interferon Regulatory Factor-7, Mice, Ikaros Transcription Factor, Quinazolinones, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
